Session Information
Date: Tuesday, September 24, 2019
Session Title: Classification of Movement Disorders
Session Time: 1:45pm-3:15pm
Location: Les Muses Terrace, Level 3
Objective: It is hypothesized that a drug delivery system that provides controlled and sustained release of PD drugs would afford better management of PD. Hollow Microbaloons composed of PMMA(polymethyl methacrylate) and poly (caprolactone) (PCL) are prepared through a modified double-emulsion technique. They are loaded with three PD drugs, i.e., levodopa (LD), carbidopa (CD), and entacapone (ENT), at a ratio of 4:1:8.
Background: Parkinson’s disease (PD) is well-known as a progressive and degenerative disease of the nervous system. The degeneration of dopaminergic neurons in the substantia nigra, and a reduction in the amount of the neurotransmitter dopamine available in the striatum relate symptoms of this disease.
Method: Microbaloons were prepared through a double emulsion (W1/O/W2) solvent evaporation method with modifications to produce hollow Microbaloons. Microbaloons were then spray coated along with ENT. The Microbaloons were analyzed for size distribution and zeta potential using Zetasizer. Shape and surface morphology were studied using SEM. Transmission electron microscope (TEM) was used as a visualizing aid for particle morpholgy. The average particle size and polydispersity index were determined by optical microscopy using a calibrated occulometer, drug entrapment, CLSM, Buoyancy tests and in-vitro drug release was studied.
Results: LD and CD are localized in both the hollow cavity and PMMA/PCL shell, while ENT is localized in the PMMA/PCL shell. Release kinetics of hydrophobic ENT is observed to be relatively slow as compared to the other hydrophilic drugs. It is further hypothesized that encapsulating ENT into PCL as a surface coating onto these Microbaloons can aid in accelerating its release. Now, these spray-coated hollow Microbaloons exhibit similar release kinetics, according to Higuchi’s rate, for all three drugs.
Conclusion: The results suggest that multiple drug encapsulation of LD, CD, and ENT in gastric floating Microbaloons could be further developed for in-vivo evaluation for the management of PD.
To cite this abstract in AMA style:
S. Bhargava. Sustained release triple drug loaded Microbaloons for management of Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/sustained-release-triple-drug-loaded-microbaloons-for-management-of-parkinsons-disease/. Accessed October 31, 2026.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/sustained-release-triple-drug-loaded-microbaloons-for-management-of-parkinsons-disease/